Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 116

1.

New techniques on uropaleopathology.

Baron MG, Benmoussa N, Bazin D, Abadie I, Daudon M, Charlier P.

Urolithiasis. 2018 Jun 5. doi: 10.1007/s00240-018-1062-x. [Epub ahead of print] No abstract available.

PMID:
29869684
2.

Correction to 'Multiple optimality criteria support Ornithoscelida'.

Parry LA, Baron MG, Vinther J.

R Soc Open Sci. 2018 Mar 14;5(3):180154. doi: 10.1098/rsos.180154. eCollection 2018 Mar.

3.

Support for the placement of Chilesaurus within Ornithischia: a reply to Müller et al.

Baron MG, Barrett PM.

Biol Lett. 2018 Mar;14(3). pii: 20180002. doi: 10.1098/rsbl.2018.0002. No abstract available.

PMID:
29593075
4.

Multiple optimality criteria support Ornithoscelida.

Parry LA, Baron MG, Vinther J.

R Soc Open Sci. 2017 Oct 25;4(10):170833. doi: 10.1098/rsos.170833. eCollection 2017 Oct. Erratum in: R Soc Open Sci. 2018 Mar 14;5(3):180154.

5.

Investigations to extend viability of a rainbow trout primary gill cell culture.

Maunder RJ, Baron MG, Owen SF, Jha AN.

Ecotoxicology. 2017 Dec;26(10):1314-1326. doi: 10.1007/s10646-017-1856-6. Epub 2017 Nov 11.

PMID:
29127661
6.

Baron et al. reply.

Baron MG, Norman DB, Barrett PM.

Nature. 2017 Nov 1;551(7678):E4-E5. doi: 10.1038/nature24012. No abstract available.

PMID:
29094705
7.

Sequential treatment with ProACT™ device implantation after male sling failure for male urinary incontinence.

Baron MG, Delcourt C, Nouhaud FX, Gillibert A, Pfister C, Grise P, Cornu JN.

Prog Urol. 2017 Dec;27(17):1098-1103. doi: 10.1016/j.purol.2017.08.001. Epub 2017 Aug 25.

PMID:
28847446
8.

A dinosaur missing-link? Chilesaurus and the early evolution of ornithischian dinosaurs.

Baron MG, Barrett PM.

Biol Lett. 2017 Aug;13(8). pii: 20170220. doi: 10.1098/rsbl.2017.0220.

9.

A new hypothesis of dinosaur relationships and early dinosaur evolution.

Baron MG, Norman DB, Barrett PM.

Nature. 2017 Mar 22;543(7646):501-506. doi: 10.1038/nature21700.

PMID:
28332513
10.

Pharmaceutical Metabolism in Fish: Using a 3-D Hepatic In Vitro Model to Assess Clearance.

Baron MG, Mintram KS, Owen SF, Hetheridge MJ, Moody AJ, Purcell WM, Jackson SK, Jha AN.

PLoS One. 2017 Jan 3;12(1):e0168837. doi: 10.1371/journal.pone.0168837. eCollection 2017.

11.

Urinary incontinence after hysterectomy.

Baron MG, Quicray M, Cornu JN.

Am J Obstet Gynecol. 2017 Apr;216(4):425-426. doi: 10.1016/j.ajog.2016.11.1023. Epub 2016 Nov 14. No abstract available.

PMID:
27856184
13.

Keeping pace with NPS releases: fast GC-MS screening of legal high products.

Elie MP, Elie LE, Baron MG.

Drug Test Anal. 2013 May;5(5):281-90. doi: 10.1002/dta.1434. Epub 2013 Jan 7.

PMID:
23297247
14.

Towards a more representative in vitro method for fish ecotoxicology: morphological and biochemical characterisation of three-dimensional spheroidal hepatocytes.

Baron MG, Purcell WM, Jackson SK, Owen SF, Jha AN.

Ecotoxicology. 2012 Nov;21(8):2419-29. doi: 10.1007/s10646-012-0965-5. Epub 2012 Jun 26.

PMID:
22732941
15.

Investigation into the suitability of capillary tubes for microcrystalline testing.

Elie LE, Baron MG, Croxton RS, Elie MP.

Drug Test Anal. 2013 Jul;5(7):573-80. doi: 10.1002/dta.1372. Epub 2012 May 27.

PMID:
22639448
16.
17.

Expression profile as predictor of relapse after adjuvant treatment in gastric cancer.

Sereno M, De Castro J, Cejas P, García-Cabezas MA, Belda C, Casado E, Feliu J, Gómez C, López M, Barón MG.

J Gastrointest Cancer. 2012 Jun;43(2):181-9. doi: 10.1007/s12029-011-9267-z.

PMID:
21360269
18.

Reversing microcrystalline tests--an analytical approach to recycling of microcrystals from drugs of abuse.

Elie LE, Baron MG, Croxton RS, Elie MP.

Forensic Sci Int. 2011 Apr 15;207(1-3):e55-8. doi: 10.1016/j.forsciint.2011.01.008. Epub 2011 Feb 1.

PMID:
21288671
19.

Variation in amino acid and lipid composition of latent fingerprints.

Croxton RS, Baron MG, Butler D, Kent T, Sears VG.

Forensic Sci Int. 2010 Jun 15;199(1-3):93-102. doi: 10.1016/j.forsciint.2010.03.019. Epub 2010 Apr 21.

PMID:
20413233
20.

Role of anti-Her-2 therapy in bladder carcinoma.

Marín AP, Arranz EE, Sánchez AR, Auñón PZ, Barón MG.

J Cancer Res Clin Oncol. 2010 Dec;136(12):1915-20. doi: 10.1007/s00432-010-0850-7. Epub 2010 Mar 6. Review.

PMID:
20213094
21.

Adjuvant chemotherapy for breast cancer and cognitive impairment.

Marín AP, Sánchez AR, Arranz EE, Auñón PZ, Barón MG.

South Med J. 2009 Sep;102(9):929-34. doi: 10.1097/SMJ.0b013e3181b23bf5. Review.

PMID:
19668023
22.

Bevacizumab: a safe and effective treatment in a patient with advanced colorectal cancer and repeated removal of metastases.

Castro-Carpeño Jd, Moyano MS, Sáenz EC, Belda-Iniesta C, Batlle JF, Barón MG.

Anticancer Drugs. 2009 Apr;20 Spec No 1:S7-S10.

PMID:
19352110
23.

Complete and rapid response to FOLFIRI plus bevacizumab in a patient presenting with impaired liver function and poor performance status from colon cancer liver metastases.

Belda-Iniesta C, Sáenz EC, de Castro-Carpeño J, Hernández E, Barón MG.

Anticancer Drugs. 2009 Apr;20 Spec No 1:S11-2.

PMID:
19352108
24.

Enhancement of microcrystalline identification of gamma-hydroxybutyrate.

Elie MP, Baron MG, Birkett JW.

J Forensic Sci. 2008 Jan;53(1):147-50. doi: 10.1111/j.1556-4029.2007.00620.x.

PMID:
18279251
25.

Early intervention with epoetin beta prevents severe anaemia in lung cancer patients receiving platinum-based chemotherapy: a subgroup analysis of the NeoPrevent study.

de Castro J, Belda-Iniesta C, Isla D, Dómine M, Sánchez A, Batiste E, Barón MG.

Lung Cancer. 2008 Feb;59(2):211-8. Epub 2007 Sep 17.

PMID:
17875340
26.

Immunohistochemical expression of p53, Bcl-2, COX-2, C-erb-B2, EPO-R, beta-catenin, and E-cadherin in non tumoral gastric mucous membrane.

Sereno M, García-Cabezas MA, De Castro J, Cejas P, Saenz EC, Belda-Iniesta C, Feijoo JB, Larrauri J, Nistal M, Baron MG.

Eur J Histochem. 2006 Oct-Dec;50(4):285-92.

PMID:
17213037
27.

Development of a GC-MS method for the simultaneous analysis of latent fingerprint components.

Croxton RS, Baron MG, Butler D, Kent T, Sears VG.

J Forensic Sci. 2006 Nov;51(6):1329-33.

PMID:
17199618
28.

Review of analytical techniques for arson residues.

Pert AD, Baron MG, Birkett JW.

J Forensic Sci. 2006 Sep;51(5):1033-49.

PMID:
17018079
29.

Clinical role of Sm-153 EDTMP in the treatment of painful bone metastatic disease.

Coronado M, Redondo A, Coya J, Espinosa E, Couto RM, Zamora P, Marin MD, Castelo B, Lillo ME, Frutos L, Barón MG, Curto LM.

Clin Nucl Med. 2006 Oct;31(10):605-10.

PMID:
16985364
30.

Long term responses with cetuximab therapy in glioblastoma multiforme.

Belda-Iniesta C, Carpeño Jde C, Saenz EC, Gutiérrez M, Perona R, Barón MG.

Cancer Biol Ther. 2006 Aug;5(8):912-4. Epub 2006 Aug 23.

31.

Early intervention with epoetin beta prevents severe anaemia in patients with solid tumours receiving platinum-based chemotherapy: results of the NeoPrevent study.

de Castro J, Ordóñez A, Isla D, Sánchez A, Arrivi A, Manzano JL, Barón MG.

Cancer Chemother Pharmacol. 2007 Jan;59(1):35-42. Epub 2006 Jul 28.

PMID:
16874498
32.

Measuring externalities of waste transfer stations in Israel using hedonic pricing.

Eshet T, Baron MG, Shechter M, Ayalon O.

Waste Manag. 2007;27(5):614-25. Epub 2006 Jun 8.

PMID:
16759843
33.

High-throughput techniques in breast cancer: a clinical perspective.

Espinosa E, Redondo A, Vara JA, Zamora P, Casado E, Cejas P, Barón MG.

Eur J Cancer. 2006 Mar;42(5):598-607. Epub 2006 Jan 23. Review.

PMID:
16431104
34.

Fixed dose-rate infusion of gemcitabine in combination with cisplatin and UFT in advanced carcinoma of the pancreas.

Feliu J, Sáenz JG, Jaráiz AR, Castañón C, Cruz M, Fonseca E, Lomas M, Castro J, Jara C, Casado E, León A, Barón MG.

Cancer Chemother Pharmacol. 2006 Oct;58(4):419-26. Epub 2006 Jan 11.

PMID:
16404636
35.

Biweekly regimen of cisplatin, gemcitabine and vinorelbine for advanced non-small-cell lung cancer.

de Carpeño JC, Barón MG, Aguiar J, Chacón JI, Feliu J, García MJ, Madroñal C, Colmenarejo A, Sánchez JJ, Ordóñez A; Oncopaz Cooperative Group (Spain).

Cancer Chemother Pharmacol. 2006 Aug;58(2):266-71. Epub 2005 Nov 25.

PMID:
16308698
36.

Breast cancer prognosis determined by gene expression profiling: a quantitative reverse transcriptase polymerase chain reaction study.

Espinosa E, Vara JA, Redondo A, Sánchez JJ, Hardisson D, Zamora P, Pastrana FG, Cejas P, Martínez B, Suárez A, Calero F, Barón MG.

J Clin Oncol. 2005 Oct 10;23(29):7278-85. Epub 2005 Aug 29.

PMID:
16129846
37.

MDCT pulmonary angiography: image processing tools.

Gruden JF, Tigges S, Baron MG, Pearlman H.

Semin Roentgenol. 2005 Jan;40(1):48-63. Review.

PMID:
15732561
38.

Phase II study of a fixed dose-rate infusion of gemcitabine associated with docetaxel in advanced non-small-cell lung carcinoma.

De Castro J, Lorenzo A, Morales S, Belón J, Dorta J, Lizón J, Madroñal C, Gallurt PM, Casado E, Feliu J, Barón MG; Oncopaz Cooperative Group.

Cancer Chemother Pharmacol. 2005 Feb;55(2):197-202. Epub 2004 Aug 21.

PMID:
15322824
39.

Congenital heart disease in the adult: 2004.

Baron MG, Book WM.

Radiol Clin North Am. 2004 May;42(3):675-90, vii. Review.

PMID:
15193936
40.

Irinotecan plus raltitrexed as first-line treatment in advanced colorectal cancer: a phase II study.

Feliu J, Salud A, Escudero P, López-Gómez L, Pericay C, Castañón C, de Tejada MR, Rodríguez-García JM, Martínez MP, Martín MS, Sánchez JJ, Barón MG; Oncopaz Cooperative Group and Associated Hospitals.

Br J Cancer. 2004 Apr 19;90(8):1502-7.

41.

The Role of FDG-PET in Diagnosing Suspected Tumor Recurrence Based on Increased Levels of Plasma Markers.

Maldonado A, Sancho F, Calvo FA, López N, Carrión RP, Barón MG, Trampal C, Ortega F.

Clin Positron Imaging. 1998 Sep;1(4):246. No abstract available.

PMID:
14516569
42.

Re: Folliculitis associated with weekly paclitaxel treatment.

Belda-Iniesta C, Casado E, Corral de la Calle M, Castelo B, Barón MG.

J Natl Cancer Inst. 2003 Mar 5;95(5):410. No abstract available.

PMID:
12618506
43.

Correlation of plain films and MR of the heart.

Baron MG.

Int J Cardiovasc Imaging. 2001 Dec;17(6):453-6. Review. No abstract available.

PMID:
12365543
44.

Nutrition and pharyngeal cancer: results from a case-control study in Spain.

Uzcudun AE, Retolaza IR, Fernández PB, Sánchez Hernández JJ, Grande AG, García AG, Olivar LM, De Diego Sastre I, Barón MG, Bouzas JG.

Head Neck. 2002 Sep;24(9):830-40.

PMID:
12211047
45.

Cardiac Disease in the Elderly: Radiographic Features.

Baron MG.

Am J Geriatr Cardiol. 1999 Oct;8(5):201-214.

PMID:
11416516
46.

The cardiac silhouette.

Baron MG.

J Thorac Imaging. 2000 Oct;15(4):230-42. Review.

PMID:
11039611
47.

Gemcitabine plus vinorelbine in nonsmall cell lung carcinoma patients age 70 years or older or patients who cannot receive cisplatin. Oncopaz Cooperative Group.

Feliu J, López Gómez L, Madroñal C, Espinosa E, Espinosa J, Girón CG, Martínez B, Castro J, De la Gándara I, Barón MG.

Cancer. 1999 Oct 15;86(8):1463-9.

PMID:
10526274
48.

Plain film diagnosis of common cardiac anomalies in the adult.

Baron MG.

Radiol Clin North Am. 1999 Mar;37(2):401-20, vi. Review.

PMID:
10198650
49.

Role of interferon alfa-2b in the induction and maintenance treatment of low-grade non-Hodgkin's lymphoma: results from a prospective, multicenter trial with double randomization.

Arranz R, García-Alfonso P, Sobrino P, Zamora P, Carrión R, García-Laraña J, Pérez G, López J, Lavilla E, Lozano M, Rayón C, Colomer R, Barón MG, Flores E, Pérez-Manga G, Fernández-Rañada JM.

J Clin Oncol. 1998 Apr;16(4):1538-46.

PMID:
9580385
50.

Worsening psoriasis after treatment with G-CSF in a patient with small-cell lung cancer.

Feliu J, Díaz R, Contreras F, Casado M, Espinosa E, Barón MG.

J Natl Cancer Inst. 1997 Sep 3;89(17):1315-6. No abstract available.

PMID:
9293924

Supplemental Content

Loading ...
Support Center